ArticleNature communications2025
Metabolomics and proteomics reveal blocking argininosuccinate synthetase 1 alleviates colitis in mice.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Metabolomics and Proteomics Analyses Reveal the Protective Effect of Crocetin Against Depressive-Like Behaviors Mice.Neurochemical research · 2026Article
- Integrated Microbiome and Metabolomics Analysis Reveals ThatFoods (Basel, Switzerland) · 2026Article
- Article
- Exploring the mechanism of Qinlian Yuyang Decoction in the treatment of ulcerative colitis based on multi-omics technology.Chinese medicine · 2026Article
- Spermine Ameliorates DSS-Induced Ulcerative Colitis in Mice by Improving Mitophagy and Intestinal Microbiota.Life (Basel, Switzerland) · 2026Article
- Magnesium Deficiency Accelerates Gut Aging and Increases Susceptibility to Colitis.Aging cell · 2026Article
- A novel biomimetic nanozyme orchestrates ulcerative colitis resolution by targeting KEAP1-NRF2-ARE pathway: Redox balance restoration, colonic barrier repair, immune homeostasis regulation.Materials today. Bio · 2026Article
- Gegen Qinlian decoction alleviates DSS-induced colitis in mice through coordinated modulation of gut microbiota, serum metabolome, and colonic γδT cell responses.Frontiers in immunology · 2026Article
- Amino Acid Metabolic Enzymes in Gastric Cancer: Roles and Mechanisms in Tumorigenesis and Progression.Oncology research · 2026Review
- Microbiota-driven therapeutic efficacy of Hyperoside in ulcerative colitis and associated anxiety.Frontiers in cellular and infection microbiology · 2026Article
- Macrophages in Ulcerative Colitis: Immunomodulatory Roles, Phenotypic Switching, and Therapeutic Targeting.Journal of innate immunity · 2026Review
- Evodiamine Inhibits Colorectal Cancer by Downregulating ASS1 via Wnt/β-Catenin/c-MYC Pathway to Block Arginine Synthesis.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, treating ulcerative colitis (UC) remains a significant challenge due to its complex etiology. In this study, metabolomics and proteomics analysis for multi-center cohorts reveal that both serum arginine levels and the rate-limiting enzyme argininosuccinate synthetase 1 (ASS1) are significantly elevated in UC patients. Exogenous arginine infusion and ASS1 overexpression exacerbate the pathological features of colitis in mice, while inhibiting or silencing ASS1 offers protection against experimental colitis. The induction of ASS1 is accompanied by increased levels of acetylated H3 and trimethylated H3K4, along with decreased levels of dimethyl H3K9 around the ASS1 promoters, suggesting epigenetic activation of ASS1 in colitis. The ASS1/arginine axis triggers mTOR and iNOS activation and induces gut microbiota dysbiosis, leading to experimental colitis. Additionally, we identify a screened compound, C-01, which significantly improves colitis by highly binding to ASS1. Our findings suggest that ASS1 could be a promising target for UC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.